TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

THE GOOD
Approvals & Labels

Sanofi, Regeneron land EMA Dupixent COPD approval
Monoclonal antibody, chronic obstructive pulmonary disease - Read more

J&J gains both FDA and EMA approval for drug-resistant TB therapy
Small molecule, multidrug-resistant (MDR) pulmonary tuberculosis (TB) - Read more

Cepheid handed FDA pass for hepatitis C test
Blood test, diagnostics, hepatitis C - Read more

THE GOOD
Business Development

GSK purchases flu, COVID-19 mRNA vaccine assets from CureVac
CureVac to receive $430M upfront, $1.13B biobucks
Vaccine, mRNA, flu, COVID-19 - Read more

THE GOOD
Fundraises

Flagship Pioneering appears to be aiming for an upsized eight fund - up $500M to $3.5B total - Read more [Paywall]

Beacon Therapeutics $170M Series B
Gene therapy, eye diseases, X-linked retinitis pigmentosa - Read more

Endeavor Ventures Funds and Keiretsu Forum signs strategic collaboration
Healthcare investing, life science investing - Read more

THE GOOD
Mergers & Acquisitions

Pentixapharm acquires Glycotope’s antibody discovery wing
Terms not disclosed
Radiopharmaceuticals, monoclonal antibody, drug discovery - Read more

Quest Diagnostics purchases LifeLabs
$985M, cash & debt
Laboratory testing, diagnostics - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Roche takes a Ph3 lung cancer L
Monoclonal antibody, lung cancer - Read more

THE BAD
Lawsuits

Boehringer Ingelheim’s attempted medicare price negotiation legal challenge is blocked in Connecticut court
Drug pricing, Medicare - Read more 

Mississippi judge denies PhRMA, Novartis’ attempted takedown of 340B state law
Compounding, drug discounts - Read more

THE BAD
Layoffs

Apollomics cuts staff, including two execs, to keep the lights on
Small molecule, lung cancer - Read more

CureVac cuts 30% of their staff during restructuring efforts
Vaccine, COVID-19, mRNA - Read more

THE BAD
Partnerships

Servier, Pieris Pharmaceuticals call it quits over safety concerns
Fusion protein, immuno-oncology, cancer - Read more

THE BAD
Research

Covid-19 virus can persist years after infection; study
Covid-19 - Read more [Paywall]

Potential correlation between semaglutide use and a rare eye condition; study
GLP-1, obesity, weight loss, diabetes, non-arteritic anterior ischemic optic neuropathy - Read more

THE UGLY
Lawsuits

Didn’t see that coming; Roche goes after Stanford University and spin-out Foresight Diagnostics on trade secret grounds
Genomic cancer detection, blood test, diagnostics - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.